Cartesian Therapeutics Inc. (RNAC), a clinical-stage biotechnology company, on Tuesday shared positive updates on its Phase 2b trial of Descartes-08, an mRNA therapy for generalized myasthenia gravis.
In the trial, Descartes-08 led to a 5.5-point reduction in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score by Month 4.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com